Final results of the Randomised Evaluation of short-term DUal antiplatelet therapy in patients with acute Coronary syndromE treated with a new generation stent (REDUCE) trial.

CONCLUSIONS: The results show that among ACS patients treated with COMBO, 3 months is non-inferior to 12 months DAPT. However, given the numerically higher rates of mortality and ST in the 3 months DAPT group, 1-year DAPT should still be recommended in ACS until more information becomes available. A 3 months DAPT strategy should be considered only if clinically mandated. PMID: 31422929 [PubMed - as supplied by publisher]
Source: EuroIntervention - Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research